zika
viru
zikv
mosquitoborn
flaviviru
caus
devast
microcephali
congenit
syndrom
infant
born
infect
pregnant
women
well
syndrom
infect
adult
issu
molecular
therapi
sariy
et
al
present
evid
demonstr
rilpivirin
us
food
drug
administr
fda
approv
hiv
drug
inhibit
zikv
rnadepend
rna
polymeras
rdrp
lead
potent
antizikv
activ
cell
cultur
mice
studi
highlight
potenti
repurpos
clinic
approv
drug
possibl
prevent
treatment
zikv
infect
associ
diseas
although
emerg
infecti
diseas
recogn
mani
decad
last
year
mark
unpreced
emerg
sever
devast
epidem
zoonot
rna
viral
diseas
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
ebola
nipah
chikungunya
west
nile
yellow
fever
zikv
given
unpredict
natur
emerg
pathogen
approach
rapid
develop
countermeasur
activ
pursu
academia
industri
besid
vaccin
transmiss
control
eg
vector
control
mosquitoborn
pathogen
antivir
therapi
import
countermeasur
prevent
treat
block
viral
transmiss
new
drug
usual
take
year
develop
drug
repurpos
activ
pursu
rapid
approach
emerg
reemerg
pathogen
compar
convent
screen
compound
librari
inhibitor
drug
repurpos
advantag
speed
low
cost
respons
recent
emerg
zikv
sever
group
perform
drugrepurpos
screen
screen
identifi
activ
compound
zikv
howev
inhibitor
low
potenc
cell
cultur
vivo
efficaci
report
take
repurpos
approach
sariy
et
al
identifi
hiv
drug
rilpivirin
antizikv
inhibitor
cell
cultur
mous
model
block
viral
rdrp
figur
first
sariy
et
al
found
human
primari
astrocyt
suscept
zikv
infect
sever
human
cell
type
includ
fetal
microglia
fetal
neuron
neural
progenitor
cell
use
zikv
infect
astrocyt
screen
assay
identifi
rilpivirin
zikv
inhibitor
eight
fdaapprov
hiv
nucleosid
nonnucleosid
revers
transcriptas
drug
rilpivirin
nonnucleosid
inhibitor
suppress
zikv
rna
replic
mm
concentr
higher
suscept
astrocyt
cell
type
zikv
infect
intrigu
previou
studi
suggest
zikv
preferenti
infect
human
neural
progenitor
cell
sinc
zikv
propos
potenti
oncolyt
virotherapi
glioblastoma
understand
suscept
cell
type
human
brain
essenti
gaug
potenti
advers
effect
caus
nonspecif
infect
kill
nontumor
cell
remain
test
rilpivirin
also
inhibit
close
relat
flavivirus
dengu
yellow
fever
west
nile
japanes
enceph
virus
nevertheless
author
establish
antivir
activ
rilpivirin
zikv
cell
cultur
second
sariy
et
al
provid
five
line
evid
support
rilpivirin
target
zikv
rdrp
figur
solv
crystal
structur
rilpivirinerdrp
complex
compound
soak
cocrystal
uncov
exact
compound
bind
pocket
enabl
ration
design
analog
improv
potenc
select
zikv
variant
resist
rilpivirin
identifi
mutat
like
map
viral
rdrp
gene
third
sariy
et
al
demonstr
vivo
efficaci
rilpivirin
zikv
interferon
b
receptor
ifnar
mous
type
interferon
receptor
knockout
model
figur
treatment
zikvinfect
ifnar
mice
rilpivirin
reduc
organ
viral
burden
weight
loss
improv
clinic
score
prevent
death
untreat
mous
brain
viral
rna
detect
astrocyt
microgliamacrophag
cell
neuron
neural
progenitor
cell
addit
zikv
infect
caus
signific
inflamm
abund
apoptoticnecrot
cell
damag
treatment
rilpivirin
reduc
level
viral
rna
brain
hippocampu
frontal
cortex
prevent
apoptoticnecrot
cell
damag
elimin
inflamm
result
indic
rilpivirin
suppress
viral
replic
diseas
develop
howev
notabl
compound
treatment
complet
prevent
weight
loss
brain
inflamm
suggest
improv
potenc
may
requir
better
vivo
efficaci
nevertheless
vivo
potenc
rilpivirin
seem
better
sofosbuvir
hepat
c
viru
hcv
nucleosid
drug
report
antizikv
activ
specif
rilpivirin
complet
protect
zikvinfect
mice
death
wherea
sofosbuvir
nucleosid
inhibitor
confer
partial
protect
studi
sariy
et
al
provid
good
exampl
repurpos
clinic
drug
potenti
treatment
zikv
infect
repurpos
drug
work
compound
exposur
level
must
greater
efficaci
concentr
repurpos
indic
sinc
human
exposur
level
approv
drug
usual
known
compound
human
exposur
level
ec
valu
drug
concentr
requir
inhibit
viral
replic
may
readili
advanc
clinic
trial
new
indic
rilpivirin
inhibit
zikv
ec
singledigit
nanomolar
micromolar
rang
respect
potenc
zikv
need
improv
ensur
clinic
efficaci
patient
achiev
goal
rilpivirin
analog
previous
synthes
lead
optim
could
test
zikv
zikv
may
differ
structureandact
sar
relationship
compound
better
potenc
zikv
may
identifi
rilpivirin
analog
meanwhil
effort
could
made
solv
cocryst
structur
compoundrdrp
complex
structur
inform
could
use
ration
design
previous
shown
dengu
rdrp
inhibitor
addit
compound
improv
potenc
could
also
test
pregnant
mous
model
prevent
maternaltofet
viral
transmiss
collect
studi
sariy
et
al
reinforc
potenti
drug
repurpos
therapeut
develop
emerg
reemerg
pathogen
